| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Laboratory of Autoimmunity, Torrey Pines Institute for Molecular Studies and
La Jolla Institute for Allergy and Immunology, San Diego, CA 92121
Natural Killer T (NKT) cells recognize both self and foreign lipid Ags presented by CD1 molecules. Although presentation of the marine sponge-derived lipid 
GalCer to type I NKT cells has been well studied, little is known about self-glycolipid presentation to either type I or type II NKT cells. Here we have investigated presentation of the self-glycolipid sulfatide to a type II NKT cell that specifically recognizes a single species of sulfatide, namely lyso-sulfatide but not other sulfatides containing additional acyl chains. In comparison to other sulfatides or GalCer, lyso-sulfatide binds with lower affinity to CD1d. Although plate-bound CD1d is inefficient in presenting lyso-sulfatide at neutral pH, it is efficiently presented at acidic pH and in the presence of saposin C. The lysosomal trafficking of mCD1d is required for GalCer presentation to type I NKT cells, it is not important for presentation of lyso-sulfatide to type II NKT cells. Consistently, APCs deficient in a lysosomal lipid-transfer protein effectively present lyso-sulfatide. Presentation of lyso-sulfatide is inhibited in the presence of primaquine, concanamycin A, monensin, cycloheximide, and an inhibitor of microsomal triglyceride transfer protein but remains unchanged following treatment with brefeldin A. Wortmannin-mediated inhibition of lipid presentation indicates an important role for the PI-3kinase in mCD1d trafficking. Our data collectively suggest that weak CD1d-binding self-glycolipid ligands such as lyso-sulfatide can be presented via the secretory and endosomal compartments. Thus this study provides important insights into the exogenous self-glycolipid presentation to CD1d-restricted T cells.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work is supported by grants from the National Institutes of Health to V.K.
2 Address correspondence and reprint requests to Dr. Vipin Kumar, Laboratory of Autoimmunity, Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, CA 92121. E-mail address: Vkumar{at}tpims.org
3 Abbreviations used in this paper: β2m, β2-microglobulin; WT, wild type; TD, tail deleted; IEF, isoelectric focusing; CMA, concanamycin A; ER, endoplasmic reticulum; EE, early endosome; RE, recycling endosome; iNKT, invariant NKT.
This article has been cited by other articles:
|
|
 |
|
  T. R. F. Smith, X. Tang, I. Maricic, Z. Garcia, S. Fanchiang, and V. Kumar Dendritic Cells Use Endocytic Pathway for Cross-Priming Class Ib MHC-Restricted CD8{alpha}{alpha}+TCR{alpha}{beta}+ T Cells with Regulatory Properties J. Immunol., June 1, 2009; 182(11): 6959 - 6968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Khan, R. M. Gallo, G. J. Renukaradhya, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz Statins Impair CD1d-Mediated Antigen Presentation through the Inhibition of Prenylation J. Immunol., April 15, 2009; 182(8): 4744 - 4750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yuan, S.-J. Kang, J. E. Evans, and P. Cresswell Natural Lipid Ligands Associated with Human CD1d Targeted to Different Subcellular Compartments J. Immunol., April 15, 2009; 182(8): 4784 - 4791. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
